TruScreen Limited announced that its newly commissioned facility to manufacture the diagnostic Opto-electric front end component of its device in Australia, is now fully operational. The facility, located in the Industry Collaboration Hub at the Commonwealth Scientific and Industrial Research Organisation site in Lindfield Sydney, benefits from knowledge sharing with both the CSIRO and other high technology organizations co-located at the site. Commissioned in June 2018 the facility produces the key technical diagnostic component of the Truscreen2 device and involves unique and sophisticated opto-electric and biomedical engineering skills and techniques. The facility is accredited under the company's internationally recognized ISO:13485 Quality Certification and includes a skilled team recruited for their specific expertise in optical and biomedical engineering. Many of the processes involved are unique to the company, and utilize componentry specifically designed by the company for its unique manufacturing needs. Output of the new facility is currently 100 front ends per month which is approximately double the output under the previous outsourced supply model. As demand for TruScreen increases, this manufacturing capacity can again be doubled up to 200 units per month. For every 100 devices fully deployed in a hospital environment in China, a sustainable annuity income stream of approximately $1.4 million will be generated every year. The majority of this increased production capacity is required to meet future demand expectations from the Chinese market.